BeiGene bags blockbuster deal with Anti-PD-1 Antibody Tislelizumab

BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene  $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…

Read More

EQRx and Equivalars: A new biotech with a potentially radical business model

Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…

Read More

USD 6.3B of VC/PE investment in lifescience firms in Jan’21

We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…

Read More

Opponents of Farm Bills need to see Budget figures on MSP based procurement

The data shared by the Union Government as part of the Budget process for fiscal 21-22 should allay concerns of those thinking that the new farm bills spell doomsday for farmers. The activists fronting for the farmers are claiming the government will do away with Minimum Support Price (MSP), stop…

Read More

USD 4.5B of VC / PE investment seen in Lifesciences spaces in December 2020

We recorded 78 VC/PE transactions pertaining to the global life sciences sector for Dec 2020, aggregating to a sum of USD 4.5B. USA recorded 46 transactions for with total investment of USD 2.1B. China reported investment of USD 1.9B over 14 VC/PE transactions. China also reported 3 IPOs  aggregating a…

Read More

USD 4.7B of VC/PE investment seen in Lifesciences spaces in November 2020

We recorded 81 VC/PE transactions pertaining to the global life sciences sector for Nov 2020, aggregating to a sum of USD 4.7B. USA recorded 46 transactions for with total investment of USD 2.5B. Around 67% of investment, spread over 40 transactions, went into supporting R&D stage companies. Vaccine companies continued…

Read More

Burger King has outperformed McDonald’s partner WestLife

An IPO of a company in the food business always arouses market interest. The IPO of Burger King India Limited opens next week. While going through the RHP, one data point struck us as interesting: since Burger King entered the market in India, it has matched WestLife Development for incremental…

Read More

Chemcrux delivers steady performance in FY21 first half despite Covid

Chemcrux Enterprise is a Specialty Chemical company listed on the BSE SME platform. Chemcrux manufactures import-substitute chemicals that go into manufacture of pharma APIs and pigments. Some of its key products are variants of Chloro Benzoic Acids and Nitro Benzoic Acid. The company’s results for first half of FY20-21 show…

Read More

Growth returned to the cement industry in Jul-Sep’20 quarter

Growth in the cement industry came back in Jul-Sep’20 quarter, as can be seen from the results of India’s top 2 cement companies. From the investor deck of India’s largest cement company Ultratech Cements: Cement demand rebound in Q2 FY21, with most regions reporting YoY growth. Volume growth was 8%…

Read More

USD 5.6B of investments into Lifesciences startups in September’20

We recorded 96 VC/PE transactions pertaining to the global life sciences sector for Sep 2020, aggregating to a sum of USD 5.6B. USA recorded 52 transactions for with total investment of USD 2.6B. China reported investment of USD 1.5B over 16 VC/PE transactions. China also reported 2 IPOs aggregating to…

Read More